Re: Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: The radiation therapy oncology group [0831] randomized clinical trial

摘要

Pisansky et al. are to be commended for their double-blind, 76-site international study examining the use of daily tadalafil to evaluate the recovery of erectile function after radiation therapy for prostate cancer (PCa). Men undergoing either external-beam radiation therapy (EBRT) or brachytherapy were enrolled and randomized to either the phosphodiesterase type 5 inhibitor (PDE5-I) tadalafil (5 mg) or placebo. In total, 112 men received tadalafil and 109 received placebos for 24 consecutive weeks commencing 7 d after initiation of radiation treatment. The primary end point was unaided erectile function 28-30 wk after radiation therapy (4-6 wk following cessation of the randomized medication). Erectile function was retained to similar degrees in the study arms at both 6 mo and 12 mo, with no significant differences observed in any sub-domain of the International Index of Erectile Function.